RecruitingPhase 2NCT06568562

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

PRO-XL: A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 (177Lu)-PSMA-617

Sponsor

University of Utah

Enrollment

32 participants

Start Date

Dec 9, 2024

Study Type

INTERVENTIONAL

Conditions

Metastatic Castration-resistant Prostate Cancer

Summary

The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is an oral tablet that will be taken once a day. Participants will return to clinic for regular visits for checkups and tests.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a drug called XL092 in men with metastatic castration-resistant prostate cancer (mCRPC) — prostate cancer that has spread to other parts of the body and keeps growing despite treatment to lower testosterone levels. It is specifically for patients whose cancer progressed after a treatment called lutetium-177 PSMA therapy (a radioactive drug that targets prostate cancer cells). **You may be eligible if:** - You are 18 or older with confirmed prostate adenocarcinoma that has spread (metastatic) - Your cancer progressed after lutetium-177 PSMA-617 treatment - Your general health is acceptable (ECOG score 2 or lower) - Your blood counts, kidney, and liver function are within required ranges **You may NOT be eligible if:** - You have small cell or neuroendocrine prostate cancer - Your cancer has not been treated with lutetium-177 PSMA therapy yet - You have severe organ dysfunction - You do not meet the blood or organ function requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGXL092

XL092 will be supplied as a tablet that will be taken at home once a day. Participants should drink at least 8 ounces of water with each dose of XL092. Participants should not eat at least 2 hours before taking the dose and 1 hour after. Participants will be given enough XL092 to take at home for a full cycle.